Back to search results

Zilovertamab Vedotin for Diffuse Large B-cell Lymphoma

This study is looking for a better way to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL), a fast-growing blood cancer. Researchers want to see if a combination of zilovertamab vedotin and R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) works better than polatuzumab vedotin and R-CHP. They will measure how many people experience a complete response (cancer goes away) with each treatment. You may be able to join if you are 18 or older and have a confirmed diagnosis of GCB DLBCL. The study aims to enroll 594 participants.

Study design
This interventional study plans to enroll 594 participants. It compares two different treatment combinations for diffuse large B-cell lymphoma.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to approximately 31 months to assess complete response rates.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06890884

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Recruiting
PHASE2Ages 18+InterventionalTreatment
Merck Sharp & Dohme LLC
~594 participants
Updated 2026-09-11 on ClinicalTrials.gov
What's tested:Zilovertamab vedotinRituximabCyclophosphamideDoxorubicinRituximab BiosimilarPrednisone

At a glance

Recruiting sites
142 of 144 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Complete Response Rate (CRR) at End of Treatment (EOT) per Lugano Response Criteria
Measured over Up to approximately 31 months

Conditions

Lymphoma, Large B-Cell, Diffuse

Explore related trials

Diffuse Large B-Cell Lymphoma

NCT06890884

Where you'd take part

This study runs at 144 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Abramson Cancer Center and Perelman Center for Advanced Medicine ( Site 0131)

    Philadelphia, Pennsylvaniastudy coordinator listed

    Recruiting

  • Aichi Cancer Center ( Site 1007)

    Nagoya, Aichi-ken, Japanstudy coordinator listed

    Recruiting

  • AIDPORT Sp. z o.o. ( Site 0808)

    Skórzewo, Greater Poland Voivodeship, Polandstudy coordinator listed

    Recruiting

  • Alliance Cancer Specialists (ACS) ( Site 8010)

    Sellersville, Pennsylvaniastudy coordinator listed

    Recruiting

  • Arcispedale Santa Maria Nuova ( Site 0706)

    Reggio Emilia, Italystudy coordinator listed

    Recruiting

  • Atlantic Health Morristown Medical Center ( Site 0163)

    Morristown, New Jerseystudy coordinator listed

    Recruiting

  • AZ Delta ( Site 0303)

    Roeselare, West-Vlaanderen, Belgiumstudy coordinator listed

    Recruiting

  • AZ Sint Jan Brugge-Oostende ( Site 0308)

    Bruges, West-Vlaanderen, Belgiumstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Medical Director · STUDY_DIRECTOR · Merck Sharp & Dohme LLC

Who to contact

Toll Free Number
[email protected]
1-888-577-8839
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Has histologically confirmed diagnosis of germinal center B-cell (GCB) subtype of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, according to the World Health Organization (WHO) classification of neoplasms of the hematopoietic and lymphoid tissues.
Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale.
Has received no prior treatment for their DLBCL.
Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART).
Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load prior to randomization.
Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening.

Exclusion

Has a history of transformation of indolent disease to DLBCL.
Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) or Grey zone lymphoma.
Has Ann Arbor Stage I DLBCL.
Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\<6 months prior to enrollment), myocardial infarction (\<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication.
Has clinically significant pericardial or pleural effusion.
Has ongoing Grade \>1 peripheral neuropathy.
Has a demyelinating form of Charcot-Marie-Tooth disease.
HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
Has ongoing corticosteroid therapy.
Known additional malignancy that is progressing or has required active treatment within the past 2 years.
Known active central nervous system (CNS) lymphoma.
Has active autoimmune disease that has required systemic treatment in the past 2 years.
Has active infection requiring systemic therapy.
Has active HBV (defined as HBsAg positive and detectable HBV deoxyribonucleic acid (DNA)) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid (RNA)) infection.
Has history of stem cell/solid organ transplant.

What this trial measures

  • Complete Response Rate (CRR) at End of Treatment (EOT) per Lugano Response CriteriaUp to approximately 31 months

    CRR at EOT is defined as the percentage of participants who experience complete response (CR) per Lugano response criteria as assessed by blinded independent central review (BICR) at end of treatment. CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. Participants with missing data or who discontinue treatment or study prior to reaching EOT will be considered non-responders and included in the total number of participants.